A Study on the Effectiveness of Antioxidant Supplementation in Tinnitus

NCT04105426 | Completed Phase 2

• 1 other identifier: 4354
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the effectiveness of antioxidant supplementation in idiopathic tinnitus patients. To investigate this, a double-blind, randomized, and placebo-controlled clinical trial was conducted to assess the impact of a multivitamin-multimineral supplement with phytochemicals combined with a-lipoic acid supplements on serum oxidative stress, serum antioxidant capacity and tinnitus parameters in patients with idiopathic tinnitus. Subjective, idiopathic, non-pulsatile tinnitus ("tinnitus") is perception of sound without the presence of an external acoustic stimulus. Causes of idiopathic tinnitus remain unknown and the pathological mechanisms are not fully understood. Currently, effective therapies for tinnitus remain limited. Previous research has demonstrated that oxidative stress is possibly involved in the pathogenesis of idiopathic tinnitus and some studies have shown beneficial effects of antioxidant therapy in tinnitus patients. Moreover, many studies have shown the beneficial effect of antioxidant supplementation on the reduction of oxidative stress and the increase of endogenous antioxidant enzymes and antioxidant capacity. Seventy patients with idiopathic tinnitus were enrolled based on certain inclusion and exclusion criteria. Subsequently, they were informed regarding the aims, methods, anticipated benefits, and potential hazards of the study, and were provided with the information leaflet of the study. Each patient who agreed to take part in the study, signed an informed consent form, a copy of which was given to them. Participants were allocated to either antioxidant or placebo group. Randomisation was conducted by someone who was not involved in the study and blinding was strictly maintained to researchers and participants. The antioxidant group received one multivitamin and multimineral tablet with grape seed extract once a day together with one tablet of alpha-lipoic acid twice a day, whereas the placebo group received identical placebo tablets. Supplements were kindly donated by Lamberts. The intervention lasted 3 months. Both groups kept their usual medical treatment and their diet and exercise habits stable during the intervention. Patients were assessed after randomisation according to the following tools:

• Medical history
• Audiometric and Tinnitus assessment: Basic audiometric tests, pitch match, loudness match, minimum masking level (MML)
• Tinnitus questionnaires: Tinnitus Handicap Inventory (THI), Tinnitus Functional Index (TFI) and Visual Analogue Scale (VAS)
• anthropometrics: body weight , height, Body Mass Index, waist and hip circumferences
• Nutrition and physical activity evaluation
• Adherence to the Mediterranean dietary pattern (MedDietScore)
• Psychological assessment
• Biochemical measurements: Complete blood count, lipid profile, glucose, electrolytes, liver enzymes, thyroid hormones
• Vitamin laboratory tests
• Oxidative stress assessment in serum samples: Total Antioxidant Capacity (TAC), Superoxide Dismutase (SOD) activity and Oxidized LDL are quantified. Compliance and any side effects were checked with a weekly telephone contact with the patients. The consumption of tablets was checked with a diary completed by patients. At the end of the intervention, all baseline parameters were assessed.

Conditions

Tinnitus

Outcome Measures

Primary Outcomes (2)

• Tinnitus loudness (in decibel) assessed by loudness matching test

  Mean Change from Baseline in Tinnitus loudness at three months assessed by Loudness matching audiometric test

  Change in tinnitus loudness was assessed at 3 months from baseline in tinnitus patients

• Tinnitus Handicap Inventory Questionnaire score (ranging from 0 to 100) which assesses the impact of tinnitus on daily life

  Mean Change from Baseline in Tinnitus Handicap Inventory Questionnaire at three months

  Change in Tinnitus Handicap Inventory score was assessed at 3 months from baseline in tinnitus patients

Secondary Outcomes (8)

• Tinnitus frequency (in Hz) assessed by pitch match test

  Change in Tinnitus frequency was assessed at 3 months from baseline in tinnitus patients

• Tinnitus Functional Index questionnaire score (ranging from 0 to 100) which assesses the impact of tinnitus on daily life

  Change in Tinnitus Functional Index score was assessed at 3 months from baseline in tinnitus patients

• serum Total Antioxidant Capacity (mM)

  Change in Serum Total Antioxidant Capacity was assessed at 3 months from baseline in tinnitus patients

• Vitamins B12, E, C, B2, B1, B6 and folic acid in blood

  Change in vitamin levels were assessed at 3 months from baseline in tinnitus patients

• Tinnitus Minimum Masking Level (in decibel)

  Change in Tinnitus Minimum Masking Level was assessed at 3 months from baseline in tinnitus patients

Study Arms (2)

Antioxidants

ACTIVE COMPARATOR

This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.

Dietary Supplement: Antioxidants

Placebo

PLACEBO COMPARATOR

This arm of patients received placebo for 3 months.

Dietary Supplement: Placebo

Interventions

Antioxidants DIETARY_SUPPLEMENT

one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.

Antioxidants

Placebo DIETARY_SUPPLEMENT

one placebo tablet three times per day for 3 months.

Placebo

Eligibility Criteria

• Age: 25 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 25-75 years old
• Unilateral or bilateral chronic idiopathic persistent tinnitus of at least 6 months' duration
• Tinnitus Handicap Inventory score rated ≥ 4 at baseline
• With a normal audiogram or up to medium-grade neurosensory hearing loss.
• Tinnitus maskable (by noise masking) with noise at least 5 decibel
• Childbearing age with a negative pregnancy test at eligibility and baseline assessment
• Stable medication during the whole period of the 3-month intervention
• Willing and able to attend the on-study visits
• Able to read and understand the relevant study documents and rating scales and follow investigator instructions during audiologic measurements

You may not qualify if:

• Tinnitus following acute acoustic trauma, sudden deafness or traumatic head or neck injury
• Intermittent tinnitus
• Meniere's Disease, otosclerosis, acute or chronic otitis media
• Head and neck radiotherapy
• Active GI disease; active malignant diseases; autoimmune diseases; cardiovascular disease; renal or hepatic disorders; haemorrhagic diathesis
• Intake of anticoagulants; ototoxic medications; tinnitus-inducing medication (e.g. aminoglycosides, chemotherapeutics, loop diuretics, high doses of aspirin or quinine)
• Psychiatric disorders
• Unregulated diabetes mellitus, hypertension or thyroid disease
• Alcohol or drug abuse
• Vitamin or inorganic supplements, vegan or macrobiotic diet before and during the trial
• Pregnancy, lactation

Sponsors & Collaborators

• National and Kapodistrian University of Athens: lead

Study Sites (1)

General Hospital of Athens "Hippocratio", Department of Otorhinolaryngology

Athens, Greece

Location

MeSH Terms

Conditions

Tinnitus

Interventions

Antioxidants

Condition Hierarchy (Ancestors)

Hearing Disorders; Ear Diseases; Otorhinolaryngologic Diseases; Sensation Disorders; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Biological Factors; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Protective Agents; Physiological Effects of Drugs; Specialty Uses of Chemicals

Study Officials

• Ioannis Xenelis, Professor

  General Hospital of Athens "Hippocratio", Department of Otorhinolaryngology

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dietitian-Nutritionist, M.Med.Sci, PhD candidate

Study Record Dates

• First Submitted: September 23, 2019
• First Posted: September 26, 2019
• Study Start: January 10, 2019
• Primary Completion: May 25, 2019
• Study Completion: May 25, 2019
• Last Updated: November 13, 2019

Record last verified: 2019-11

Locations

GR (1)